Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Assets Average (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Assets Average for 15 consecutive years, with $189.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 12.54% to $189.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $189.9 million, a 12.54% decrease, with the full-year FY2025 number at $196.5 million, down 16.98% from a year prior.
  • Assets Average was $189.9 million for Q4 2025 at Anika Therapeutics, up from $188.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $363.9 million in Q1 2021 to a low of $188.6 million in Q3 2025.
  • A 5-year average of $294.6 million and a median of $331.2 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: decreased 0.23% in 2023, then dropped 28.14% in 2025.
  • Anika Therapeutics' Assets Average stood at $350.2 million in 2021, then dropped by 0.51% to $348.4 million in 2022, then decreased by 14.07% to $299.4 million in 2023, then dropped by 27.5% to $217.1 million in 2024, then dropped by 12.54% to $189.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Assets Average are $189.9 million (Q4 2025), $188.6 million (Q3 2025), and $189.1 million (Q2 2025).